Epigenetics in non-small cell lung carcinomas

Objective. To perform a systematic review of the main epi­genetic aberrations involved in non-small cell lung carcinomas’ (NSCLC) diagnosis, progression, and therapeutics. Materials and methods. We performed a systematic review of the scientific literature on lung cancer epigenetics, focusing on NSC...

Full description

Bibliographic Details
Main Authors: Irlanda Peralta-Arrieta, Leonel Armas-López, Joaquín Zúñiga, Federico Ávila-Moreno
Format: Article
Language:English
Published: Instituto Nacional de Salud Pública 2019-06-01
Series:Salud Pública de México
Subjects:
dna
Online Access:http://www.saludpublica.mx/index.php/spm/article/view/10089
id doaj-49fbb7582b654a628d75b936bb7231d1
record_format Article
spelling doaj-49fbb7582b654a628d75b936bb7231d12020-11-25T01:38:57ZengInstituto Nacional de Salud PúblicaSalud Pública de México0036-36342019-06-01613, may-jun31832810.21149/1008916671Epigenetics in non-small cell lung carcinomasIrlanda Peralta-Arrieta0Leonel Armas-López1Joaquín Zúñiga2Federico Ávila-Moreno3Facultad de Estudios Superiores-IztacalaFacultad de Estudios Superiores-IztacalaNational Institute of Respiratory Diseases (INER) “Ismael Cosío Villegas” Escuela de Medicina y Ciencias de la Salud, Tecnológico de Monterrey, Ciudad de México. México City. México.Facultad de Estudios Superiores Iztacala, UNAM. Instituto Nacional de Enfermedades Respiratorias.Objective. To perform a systematic review of the main epi­genetic aberrations involved in non-small cell lung carcinomas’ (NSCLC) diagnosis, progression, and therapeutics. Materials and methods. We performed a systematic review of the scientific literature on lung cancer epigenetics, focusing on NSCLC. Results. Several advances in the molecular study of classical epigenetic mechanisms and massive studies of lung cancer epigenome have contributed relevant new evidence revealing that various molecular complexes are functionally influencing genetic-epigenetic and transcriptional mechanisms that promote lung tumorigenesis (initiation, promotion, and progression), and are also involved in NSCLC therapy-resistance mechanisms. Conclusion. Several epigenetic complexes and mechanisms must be analyzed and considered for the design of new and efficient therapies, which could be fundamental to develop an integrated knowledge to achieve a comprehensive lung cancer personalized medicine.http://www.saludpublica.mx/index.php/spm/article/view/10089non-small cell lung cancerepigeneticsbiomark¬ersdna
collection DOAJ
language English
format Article
sources DOAJ
author Irlanda Peralta-Arrieta
Leonel Armas-López
Joaquín Zúñiga
Federico Ávila-Moreno
spellingShingle Irlanda Peralta-Arrieta
Leonel Armas-López
Joaquín Zúñiga
Federico Ávila-Moreno
Epigenetics in non-small cell lung carcinomas
Salud Pública de México
non-small cell lung cancer
epigenetics
biomark¬ers
dna
author_facet Irlanda Peralta-Arrieta
Leonel Armas-López
Joaquín Zúñiga
Federico Ávila-Moreno
author_sort Irlanda Peralta-Arrieta
title Epigenetics in non-small cell lung carcinomas
title_short Epigenetics in non-small cell lung carcinomas
title_full Epigenetics in non-small cell lung carcinomas
title_fullStr Epigenetics in non-small cell lung carcinomas
title_full_unstemmed Epigenetics in non-small cell lung carcinomas
title_sort epigenetics in non-small cell lung carcinomas
publisher Instituto Nacional de Salud Pública
series Salud Pública de México
issn 0036-3634
publishDate 2019-06-01
description Objective. To perform a systematic review of the main epi­genetic aberrations involved in non-small cell lung carcinomas’ (NSCLC) diagnosis, progression, and therapeutics. Materials and methods. We performed a systematic review of the scientific literature on lung cancer epigenetics, focusing on NSCLC. Results. Several advances in the molecular study of classical epigenetic mechanisms and massive studies of lung cancer epigenome have contributed relevant new evidence revealing that various molecular complexes are functionally influencing genetic-epigenetic and transcriptional mechanisms that promote lung tumorigenesis (initiation, promotion, and progression), and are also involved in NSCLC therapy-resistance mechanisms. Conclusion. Several epigenetic complexes and mechanisms must be analyzed and considered for the design of new and efficient therapies, which could be fundamental to develop an integrated knowledge to achieve a comprehensive lung cancer personalized medicine.
topic non-small cell lung cancer
epigenetics
biomark¬ers
dna
url http://www.saludpublica.mx/index.php/spm/article/view/10089
work_keys_str_mv AT irlandaperaltaarrieta epigeneticsinnonsmallcelllungcarcinomas
AT leonelarmaslopez epigeneticsinnonsmallcelllungcarcinomas
AT joaquinzuniga epigeneticsinnonsmallcelllungcarcinomas
AT federicoavilamoreno epigeneticsinnonsmallcelllungcarcinomas
_version_ 1725051226526056448